newsfilter
← Latest News
GlobeNewswire·

Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights

- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in